X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1004) 1004
Publication (66) 66
Book / eBook (50) 50
Book Chapter (13) 13
Newsletter (6) 6
Book Review (5) 5
Conference Proceeding (4) 4
Newspaper Article (3) 3
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (803) 803
index medicus (633) 633
diabetes (567) 567
male (537) 537
female (535) 535
risk factors (447) 447
middle aged (417) 417
endocrinology & metabolism (387) 387
aged (335) 335
mortality (275) 275
diabetes mellitus (268) 268
diabetes mellitus, type 2 - complications (249) 249
type 2 diabetes (247) 247
cardiovascular disease (244) 244
diabetic cardiomyopathies - epidemiology (235) 235
adult (210) 210
mellitus (205) 205
cardiac & cardiovascular systems (203) 203
prevalence (200) 200
diabetic angiopathies - epidemiology (191) 191
hypertension (187) 187
diabetics (183) 183
risk (163) 163
cardiovascular diseases - epidemiology (161) 161
heart failure (155) 155
cardiomyopathy (154) 154
care and treatment (150) 150
cardiovascular diseases (148) 148
glucose (147) 147
research (144) 144
animals (136) 136
complications (134) 134
health aspects (134) 134
cohort studies (131) 131
analysis (122) 122
diabetic cardiomyopathies - prevention & control (116) 116
heart (116) 116
cardiovascular diseases - complications (115) 115
follow-up studies (113) 113
oxidative stress (113) 113
insulin (112) 112
incidence (111) 111
diabetes mellitus, type 2 - blood (108) 108
medical research (107) 107
blood pressure (105) 105
disease (105) 105
complications and side effects (104) 104
heart attacks (102) 102
studies (102) 102
diabetic cardiomyopathy (101) 101
diabetic angiopathies - prevention & control (99) 99
heart diseases (99) 99
prognosis (98) 98
cardiovascular-disease (94) 94
epidemiology (93) 93
hypoglycemic agents - therapeutic use (93) 93
diabetes mellitus, type 2 - drug therapy (92) 92
diabetic retinopathy (90) 90
prospective studies (90) 90
medicine (89) 89
diabetes mellitus, type 2 - epidemiology (88) 88
cardiovascular diseases - prevention & control (87) 87
medicine, experimental (87) 87
risk-factors (86) 86
hyperglycemia (84) 84
cross-sectional studies (83) 83
heart-failure (82) 82
association (81) 81
echocardiography (80) 80
research article (80) 80
diabetes mellitus, type 1 - complications (79) 79
insulin resistance (78) 78
diagnosis (77) 77
aged, 80 and over (76) 76
diabetic cardiomyopathies - physiopathology (75) 75
diabetes mellitus, type 2 - physiopathology (74) 74
metabolism (73) 73
review (73) 73
body mass index (72) 72
insulin-resistance (72) 72
population (70) 70
health risk assessment (69) 69
patients (68) 68
diastolic dysfunction (67) 67
obesity (67) 67
biomarkers - blood (66) 66
glycemic control (66) 66
myocardial-infarction (66) 66
comorbidity (64) 64
coronary heart disease (64) 64
diabetic angiopathies - physiopathology (64) 64
diabetic cardiomyopathies - complications (63) 63
retrospective studies (63) 63
blood glucose - metabolism (62) 62
cardiovascular (62) 62
dextrose (62) 62
diabetes mellitus - epidemiology (62) 62
dysfunction (62) 62
medicine, research & experimental (62) 62
physiological aspects (62) 62
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (38) 38
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Online Resources - Online (3) 3
Credit Valley Hospital - Stacks (2) 2
Providence Healthcare - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Credit Valley Hospital - May be requested in 6-10 wks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trillium Health Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1060) 1060
Spanish (4) 4
French (3) 3
Portuguese (3) 3
German (2) 2
Japanese (2) 2
Romanian (2) 2
Chinese (1) 1
Hungarian (1) 1
Italian (1) 1
Polish (1) 1
Romansh (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 66, Issue 21, pp. 2451 - 2466
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2016, Volume 68, Issue 2, pp. 161 - 172
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 344 - 351
Aims To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk... 
cardiovascular disease | type 2 diabetes | DPP | hypoglycaemia | dapagliflozin | diabetes complications | 4 inhibitor | DPP-4 inhibitor | REGISTER | SEVERE HYPOGLYCEMIA | MONOTHERAPY | HEART-FAILURE | PREVALENCE | COMBINATION | METFORMIN TREATMENT | INSULIN | DRUGS | ENDOCRINOLOGY & METABOLISM | DPP-4 INHIBITORS | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | DPP‐4 inhibitor | Original | Clinical Medicine | Medical and Health Sciences | Endokrinologi och diabetes | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article
Diabetes, ISSN 0012-1797, 05/2016, Volume 65, Issue 5, pp. 1370 - 1379
Journal Article
Journal Article
Journal of the American Society of Echocardiography, ISSN 0894-7317, 2011, Volume 24, Issue 11, pp. 1268 - 1275.e1
Journal Article
Diabetes obesity & metabolism, ISSN 1462-8902, 07/2017, Volume 19, Issue 7, pp. 926 - 935
Two large cardiovascular outcome trials of canagliflozin, comprising the CANVAS Program, will complete in early 2017: the CANagliflozin cardioVascular... 
cardiovascular disease | type 2 diabetes | inhibitor | SGLT2 | SGLT2 inhibitor | DESIGN | EVENTS | EFFICACY | SAFETY | RATIONALE | CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT | CONJUNCTION | BASE-LINE CHARACTERISTICS | ENDOCRINOLOGY & METABOLISM | PLACEBO-CONTROLLED TRIAL | Follow-Up Studies | Diabetic Cardiomyopathies - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Dose-Response Relationship, Drug | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Canagliflozin - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Diabetic Cardiomyopathies - prevention & control | Female | Diabetic Angiopathies - prevention & control | Equivalence Trials as Topic | Diabetes Mellitus, Type 2 - complications | Canagliflozin - administration & dosage | Hypoglycemic Agents - therapeutic use | Reproducibility of Results | Double-Blind Method | Sodium-Glucose Transporter 2 - metabolism | Mortality | Risk Factors | Diabetic Angiopathies - mortality | Biomarkers - blood | Canagliflozin - adverse effects | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - mortality | Diabetic Cardiomyopathies - epidemiology | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Hypoglycemic Agents - adverse effects | Cohort Studies | Type 2 diabetes | Clinical Trial Design